Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Safety & Regulatory Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

Impacting People's Lives

"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.

LEARN MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.

COMPLIANCE OVERVIEW
Safety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Global Trends in R&D 2024

READ MORE

EMEA Insights

"IQVIA thought leadership with a focus on EMEA.

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • IQVIA Connected Intelligence™
  • IQVIA Healthcare-grade AI™
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Patient Experience Solutions with Apple devices
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
IQVIA AI is Healthcare-grade AI

Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.

LEARN MORE

Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
IQVIA Patient Experience Solutions with Apple devices

Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.

LEARN MORE
MAIN/Careers
Careers/
WORKING AT IQVIA

Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.

LEARN MORE
LIFE AT IQVIA

Careers, culture and everything in between. Find out what’s going on right here, right now.

LEARN MORE

WE’RE HIRING

"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

SEARCH JOBS
MAIN/Contact Us
Contact Us/
Blog
Novel therapies drive growth in the atopic dermatitis market
Anwesha Chaudhuri, Consultant, IQVIA Forecast Link
David Bottom, Senior Analyst, IQVIA Forecast Link, Global Market Insights
Nov 30, 2020
  • Blogs
  • Novel therapies drive growth in the atopic dermatitis market

Based on IQVIA’s Forecast Link, this article considers how the atopic dermatitis market is expected to develop over the next 10 years, and how new product launches and generic entries are expected to shape market evolution.

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by dry skin and intense itching which often leads to skin trauma and considerable sleep disturbances. Sufferers can experience a significantly diminished quality of life, not only due to their symptoms, but the stigma of a visible skin disorder and the need for frequent applications of topical medications. Treatment consists of a stepwise approach based on the severity of symptoms including the liberal use of emollients and moisturizers for milder symptoms and topical steroids such as hydrocortisone, or topical calcineurin inhibitors such as tacrolimus, for moderate symptoms. Historically, options for severe or recalcitrant atopic dermatitis involved systemic agents such as oral steroids, cyclosporine, azathioprine and methotrexate. These therapies, however, possess potentially serious side effects and require careful monitoring, and as such, are only recommended for short-term use. Fortunately, recent advances in understanding about the pathogenesis of the disease has led to the development of novel therapies which offer significantly improved treatments for patients with moderate-to-severe disease.

According to IQVIA Forecast Link, there will be eleven new product launches for AD including products coming from the interleukin-4 and -13 (IL-4/13), phosphodiesterase-4 (PDE-4) and Janus Kinase (JAK) inhibitor classes globally between 2020 and 2029. These new launches will provide additional options for patients with moderate-to-severe disease; improve quality of life; and drive value growth in the AD market. Seven molecules, including topical steroids, second-generation oral antihistamines, an IL-4/13 and JAK inhibitor will lose patent protection during the same time period. Although the first loss of protection events for IL-4/13 and JAK inhibitors have the potential to have a greater impact, the events will occur too late in the forecast horizon to have a significant effect. Furthermore, topical steroids and oral antihistamines account for a very small percentage of market value share. As a result, loss of protection events are expected to have a negligible impact on value sales. As the newer therapies are expected to be launched at much higher implied prices on a cost per day basis and compete with existing therapies, the net impact of these events will be positive.

The availability of these new products and ongoing prescription demand will grow the global AD market by a CAGR of 10% in terms of value over the next decade reaching approximately $11.3bn by 2029. This represents a 130% increase over projected 2020 value sales. Moreover, during the same time period, the AD market will grow faster than other leading dermatological conditions such as psoriasis and psoriatic arthritis which are estimated to grow at a CAGR of 3% and 2%, respectively.

The most successful recent launch in the AD market has been dupilumab, a monoclonal antibody which inhibits IL-4/13 and is administered once every two weeks by subcutaneous injection. The drug was launched in Q2 2017 and is the first of its kind to be approved for the treatment of AD. Unlike traditional therapies, IL-4/13 inhibitors specifically target the Type II inflammation pathway which is strongly implicated in the pathogenesis of the disease. Initially approved for adults, dupilumab has expanded its indications to include adolescents, and children aged 6 to 11 years in Q1 2019 and Q1 2020, respectively. The average implied price per patient day for biologics is approximately 209 times that of non-biologics, and consequently, the drug already accounted for approximately 60% of AD value sales globally in the year to Q2 2020. Three additional IL-4/13 inhibitors are expected to launch within the next decade and while dupilumab possesses a first-to-market advantage, two of the expected new entrants are administered less frequently, i.e. once per month, providing a potential point of differentiation. By 2029, dupilumab’s share of the IL-4/13 space in the AD market is expected to decrease due to the entry of these competitors.

Crisaborole, a topical PDE-4 inhibitor and delgocitinib, an oral JAK inhibitor are other recent additions to the AD market that have driven recent historical value growth, although they have reached fewer geographies than dupilumab as of Q2 2020. JAK inhibitors exert their effect in AD by suppressing inflammation and inhibiting immune-cell activation and offer the advantage of oral administration. The exact mechanism by which topical PDE-4 inhibitors produce their effect in AD is unknown, but they improve symptoms without the need for steroids. Four additional JAK inhibitors, some of which are already approved for other indications, and one additional topical PDE-4 inhibitor are expected to gain approval for AD in the coming decade. These products are expected to be launched at a price premium compared with existing non-biologics and will increase the average implied cost per patient day of this group by 71% thereby driving value sales.

Recent launches of the subcutaneous IL-4/13 inhibitor dupilumab and topical PDE-4 inhibitor crisaborole resulted in a paradigm shift in the treatment of AD. These products offer advantages over topical steroids or systemic therapies because they are not only effective for moderate-to-severe AD, but they avoid important drawbacks of existing therapies. For example, long-term use of topical steroids can cause striae (stretch marks), petechiae (small red/purple spots), telangiectasia (small, dilated blood vessels on the surface of the skin), skin thinning, atrophy and acne. In addition, systemic therapies have a less favourable risk-benefit profile which requires careful monitoring and short-term use. While these new products are more costly, demand has already driven their collective value share to 60% of the global AD market. Several launches of new targeted therapies will occur between 2020 and 2029 that will improve quality of life for AD sufferers while driving value growth higher than is anticipated for several leading dermatology conditions.

IQVIA Forecast Link provides regularly updated and fully segmentable sales and volume forecasts across 10,000 products, 600 diseases and 73 countries. Gain insights into current and future market landscapes and power your strategic decision making via this single easy-to-use platform providing unrivalled breadth of coverage. To learn more, please view the Forecast Link Video.

 

1 Yang EJ, Sekhon S, Sanchez IM, et al. Recent Developments in Atopic Dermatitis. Pediatrics 2018;142(4):e20181102

2 Siedilkowski S, Sandhu V and Lynde C. Treatment of Atopic Dermatitis Using JAK Inhibitors: A Systematic Review. EMJ Dermatol. 2019;7(1):89-100.

3 Kapur S, Watson W and Carr, S. Atopic Dermatitis. Allergy Asthma Clin Immunol 14, 52 (2018).

Contact Us